Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China flag China · Delayed Price · Currency is CNY
51.23
-4.16 (-7.51%)
At close: Sep 30, 2026

SHE:301108 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
871.51762.82539.42592.39648.31970.23
Other Revenue
9.279.198.0330.218.2514.22
880.78772.01547.45622.59666.56984.45
Revenue Growth
53.85%41.02%-12.07%-6.60%-32.29%32.50%
Cost of Revenue
674.07584.88448.21442.27461.97667.87
Gross Profit
206.71187.1399.24180.32204.59316.58
Selling, General & Admin
82.7765.1851.4655.6838.9129.1
Research & Development
31.5328.1920.4822.5225.2936.38
Other Operating Expenses
-0.521.080.560.724.867.13
Operating Expenses
120.75104.3480.6277.6969.8473.28
Operating Income
85.9682.7918.63102.63134.75243.31
Interest Expense
-3.66-1.39-0.77-1.01-1.86-1.62
Interest & Investment Income
21.3718.9615.1730.3824.66.05
Currency Exchange Gain (Loss)
-23.77-7.522.511.226.2-6.89
Other Non Operating Income (Expenses)
-6.13-3.510.78-0.23-0.16-0.24
EBT Excluding Unusual Items
73.7689.3236.32133163.52240.61
Gain (Loss) on Sale of Investments
5.345.355.59.061.011.2
Gain (Loss) on Sale of Assets
0.750.36-0.030.321.150.29
Asset Writedown
-10.55-10.55-17.49-10.51-11.46-0.42
Other Unusual Items
22.642.10.853.137.9510.18
Pretax Income
91.9386.5825.15135.01162.16251.85
Income Tax Expense
5.429.185.9720.4621.231.81
Earnings From Continuing Operations
86.5177.419.17114.54140.97220.05
Minority Interest in Earnings
-0.16-0.130.290.66--
Net Income
86.3577.2719.46115.2140.97220.05
Net Income to Common
86.3577.2719.46115.2140.97220.05
Net Income Growth
239.16%296.97%-83.10%-18.28%-35.94%22.50%
Shares Outstanding (Basic)
12911411411411388
Shares Outstanding (Diluted)
12911411411411388
Shares Change
30.74%-0.76%0.81%0.14%29.59%2.66%
EPS (Basic)
0.670.680.171.011.242.51
EPS (Diluted)
0.670.680.171.011.242.51
EPS Growth
159.42%300.00%-83.24%-18.39%-50.57%19.32%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-30.4-268.78-21.11-1.54269.1127.59
Free Cash Flow Per Share
-0.23-2.37-0.18-0.012.371.46
Dividend Per Share
0.2700.2500.1000.2570.3570.536
Dividend Growth
35.00%150.00%-61.10%-28.00%-33.34%-
Gross Margin
23.47%24.24%18.13%28.96%30.69%32.16%
Operating Margin
9.76%10.72%3.40%16.48%20.21%24.71%
Profit Margin
9.80%10.01%3.56%18.50%21.15%22.35%
Free Cash Flow Margin
-3.45%-34.82%-3.86%-0.25%40.37%12.96%
EBITDA
131.85124.0662.83134.32169.16271.94
EBITDA Margin
14.97%16.07%11.48%21.57%25.38%27.62%
D&A For EBITDA
45.941.2844.231.6934.4128.63
EBIT
85.9682.7918.63102.63134.75243.31
EBIT Margin
9.76%10.72%3.40%16.48%20.21%24.71%
Effective Tax Rate
5.90%10.60%23.75%15.16%13.07%12.63%
Revenue as Reported
880.78772.01547.45622.59666.56984.45
Advertising Expenses
-0.080.060.40.180.05